2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Bijal Shah, MD, MS, and Michael Wang, MD, discuss navigating the referral process for CAR T-cell therapy in hematologic malignancies.
Bijal Shah, MD, MS, associate member, Department of Malignant Hematology, Moffitt Cancer Center, and Michael Wang, MD, professor, Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, discuss navigating the referral process for CAR T-cell therapy in hematologic malignancies.
Referring patients for CAR T-cell therapy can be a challenging process, Shah explains. Patients who receive CAR T-cell therapy are expected to stay in or around the treatment center for 2 to 4 weeks, depending on the severity of CAR T-cell therapy–related toxicities, Wang says.
Ultimately, close collaboration between community and academic practices is needed to ensure the referral process is optimal for patients, Shah and Wang conclude.